Efficacy of thymosin alpha-1 as an immunomodulatory adjuvant in patients with recurrent implantation failure: a real-world retrospective analysis
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20260885Keywords:
Recurrent implantation failure, Infertility, Immunomodulatory, Thymosin alpha-1Abstract
Background: Recurrent implantation failure (RIF) remains a major challenge in assisted reproductive technology (ART), affecting approximately 10–15% of couples undergoing treatment. Immune dysregulation is considered an important contributor to implantation failure. Thymosin Alpha-1, an immunomodulatory agent, has shown promising results in difficult-to-treat infertility cases. This study evaluated the real-world effectiveness of Thymosin Alpha-1 as an adjuvant therapy in patients with RIF in an Indian clinical setting.
Methods: This retrospective, observational study was conducted at a private infertility center in India. Medical records of adult women aged over 30 years diagnosed with RIF over a one-year period were analyzed. All included patients received Thymosin alpha-1 (1.6 or 3.2 mg daily or on an alternate-day regimen) for a minimum of 118 days. Demographic characteristics, comorbidities, infertility-related conditions including polycystic ovary syndrome (PCOS), endometrial features, immunological parameters, treatment regimens and outcomes were evaluated.
Results: Most patients were aged 31–35 years (41.1%), followed by 36–40 years (25.6%). Thyroid disorders (5.6%) and diabetes (2.2%) were uncommon, while 82.2% had no comorbidities; latent tuberculosis was present in 13.3%. Anovulatory cycles were observed in 17.8% of patients and 71.1% had a thin endometrium. Immunological parameters showed marked variability, including mean CD16+56 natural killer cell counts of 175±103 cells/µl and mean TNF-α levels of 18.4±41.2 pg/ml. PCOS was identified in a subset of patients. All patients with RIF (n=90) who received thymosin alpha-1 therapy for at least 118 days demonstrated positive reproductive outcomes, regardless of dosing regimen.
Conclusions: Thymosin alpha-1 therapy was associated with encouraging outcomes in patients with RIF, supporting its role as an effective immunomodulatory adjuvant.
Metrics
References
Bashiri A, Halper KI, Orvieto R. Recurrent Implantation Failure-update overview on etiology, diagnosis, treatment and future directions. Reprod Biol Endocrinol. 2018;5;16(1):121.
Ma J, Gao W, Li D. Recurrent implantation failure: A comprehensive summary from etiology to treatment. Front Endocrinol (Lausanne). 2023;5;13:1061766. DOI: https://doi.org/10.3389/fendo.2022.1061766
Cimadomo D, de Los Santos MJ, Griesinger G, Lainas G, Le Clef N. ESHRE Working Group on Recurrent Implantation Failure; ESHRE good practice recommendations on recurrent implantation failure. Hum Reprod Open. 2023;2(3):623. DOI: https://doi.org/10.1093/hropen/hoad023
Bashiri A, Halper KI, Orvieto R. Recurrent Implantation Failure-update overview on etiology, diagnosis, treatment and future directions. Reprod Biol Endocrinol. 2018;5;16(1):121.
Bashiri A, Halper KI, Orvieto R. Recurrent Implantation Failure-update overview on etiology, diagnosis, treatment and future directions. Reprod Biol Endocrinol. 2018;5;16(1):121. DOI: https://doi.org/10.1186/s12958-018-0414-2
Hirachan A, Bakshi R. Enhancing embryo implantation success: the role of alpha thymosin in modulating immune response in recurrent implantation failure. Res J Med Sci. 2024;18:306‐10 DOI: https://doi.org/10.36478/makrjms.2024.6.306.310
Dominari A, Hathaway Iii D, Pandav K, Matos W, Biswas S, Reddy G, et al. Thymosin alpha 1: A comprehensive review of the literature. World J Virol. 2020;15;9(5):67-78. DOI: https://doi.org/10.5501/wjv.v9.i5.67
Rajan A, Sampath A, Supriya MS, Dhanasekaran RK. Successful pregnancy after administration of thymosin alpha-1 in a woman with recurrent implantation failure. Int J Pharm Clin Res. 2024;6(2):73-5. DOI: https://doi.org/10.33545/26647591.2024.v6.i2b.107
Meng S, Zhang T, Li C, Zhang X, Shen H. Immunoregulatory therapy improves reproductive outcomes in elevated Th1/Th2 women with embryo transfer failure. Biomed Res Int. 2022;26:4990184. DOI: https://doi.org/10.1155/2022/4990184
Robertson SA, Care AS, Moldenhauer LM. Regulatory T cells in embryo implantation and the immune response to pregnancy. J Clin Invest. 2018;1;128(10):4224-35. DOI: https://doi.org/10.1172/JCI122182
Yang X, Qian F, He HY, Liu KJ, Lan YZ, Ni B, et al. Effect of thymosin alpha-1 on subpopulations of Th1, Th2, Th17 and regulatory T cells (Tregs) in vitro. Braz J Med Biol Res. 2012;45(1):25-32. DOI: https://doi.org/10.1590/S0100-879X2011007500159
Downloads
Published
How to Cite
Issue
Section
